e-Drug3D

872

TRAVOPROST


INN
TRAVOPROST

(has an active metabolite)

cas 157283-68-6
CLASS

SENSORY
ANTIHYPERTENSIVE
ANTIGLAUCOMA
OPHTHALMOLOGICALS
PROSTAGLANDIN ANALOGUES
FP PROSTANOID RECEPTOR AGONIST
HYDROLYZED TO THE ACTIVE FREE ACID

ROUTE (list)

OPHTHALMIC INTRACAMERAL

ATC code

S01EE04

PK parameters

Solubility

PRACTICALLY INSOLUBLE IN WATER


Target

TARGET FP PROSTANOID RECEPTOR

DrugCentral

Prostaglandin F2-alpha receptor UNIPROT P43088 PTGFR

Download SDF file propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate

Formula:
C26H35F3O6

Calculated chemical properties:

MW 500.54
NB_atoms 35
XLogP 4.43
PSA 96.337
NB_HD 3
NB_HA 6
fsp3 0.58
Lipinski(0=no;1=yes) 0

FDA
NDA 021257 (pdf not found) INN (TRAVOPROST) TRAVATAN (ALCON PHARMS LTD) APPROVAL= AP YEAR= 2001 DISCONTINUED
NDA 021994 (pdf not found) INN (TRAVOPROST) TRAVATAN Z (SANDOZ) APPROVAL= AP YEAR= 2006
NDA 091341 (pdf not found) INN (TRAVOPROST) TRAVOPROST (PAR PHARM) APPROVAL= TA YEAR= 2011
NDA 091340 (pdf not found) INN (TRAVOPROST) TRAVOPROST (CHARTWELL RX) APPROVAL= AP YEAR= 2013
NDA 204822 (pdf not found) INN (TRAVOPROST) IZBA (NOVARTIS) APPROVAL= AP YEAR= 2014 DISCONTINUED
NDA 203431 (pdf not found) INN (TRAVOPROST) TRAVOPROST (APOTEX) APPROVAL= AP YEAR= 2015
NDA 205050 (pdf not found) INN (TRAVOPROST) TRAVOPROST (MYLAN) APPROVAL= AP YEAR= 2017
NDA 210458 (pdf not found) INN (TRAVOPROST) TRAVOPROST (ALEMBIC) APPROVAL= AP YEAR= 2019 DISCONTINUED
NDA 203767 (pdf not found) INN (TRAVOPROST) TRAVOPROST (MICRO LABS) APPROVAL= AP YEAR= 2021
NDA 218010 (pdf not found) INN (TRAVOPROST) IDOSE TR (GLAUKOS) APPROVAL= AP YEAR= 2023
NDA 207040 (pdf not found) INN (TRAVOPROST) TRAVOPROST (LUPIN LTD) APPROVAL= AP YEAR= 2024 DISCONTINUED
NDA 217228 (pdf not found) INN (TRAVOPROST) TRAVOPROST (SOMERSET THERAPS LLC) APPROVAL= AP YEAR= 2024
NDA 218159 (pdf not found) INN (TRAVOPROST) TRAVOPROST (GLAND) APPROVAL= AP YEAR= 2024

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL